|
1.
|
Spyratos F, Brouillet JP, Defrenne A, et
al: Cathepsin-D: an independant prognostic factor for metastasis of
breast cancer. Lancet. 8672:1115–1118. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Foekens JA, Look MP, Bolt-de Vries J,
Meijer-van Gelder M, van Putten WLJ and Klijn JGM: Cathepsin D in
primary breast cancer: prognostic evaluation involving 2810
patients. Br J Cancer. 79:300–307. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Rochefort H, Garcia M, Glondu M, Laurent
V, Liaudet E, Rey JM and Roger P: Cathepsin D in breast cancer:
mechanisms and clinical applications a 1999 overview. Clinica
Chimica Acta. 291:157–170. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Capony F, Rougeot C, Montcourier P,
Cavaillès V, Salazar G and Rochefort H: Increased secretion altered
processing, and glycosylation of pro-cathepsin D in human mammary
cancer cells. Cancer Res. 49:3904–3909. 1989.PubMed/NCBI
|
|
5.
|
Rochefort H, Capony F and Garcia M:
Cathepsin D: a protease involved in breast cancer metastasis.
Cancer Metastasis Rev. 9:321–331. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Veith FO, Capony F, Garcia M, Chantelard
J, Pujol H, Veith F, Zajdela A and Rochefort H: Release of
estrogen-induced glycoprotein with a molecular weight of 52,000 by
breast cancer cells in primary culture. Cancer Res. 43:1861–1868.
1983.PubMed/NCBI
|
|
7.
|
Stubbs M, McSheehy PM and Griffiths JR:
Causes and consequences of acidic pH in tumors: a magnetic
resonance study. Adv Enzyme Regul. 39:13–30. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Martin GR and Jain RK: Measurement of
interstitial pH profiles in normal and neoplastic tissue using
fluorescence ratio imaging microscopy. Cancer Res. 54:5670–5674.
1994.PubMed/NCBI
|
|
9.
|
Foekens JA, Peters HA, Look MP, et al: The
urokinase system of plasminogen activation and prognosis in 2,780
breast cancer patients. Cancer Res. 60:636–643. 2000.PubMed/NCBI
|
|
10.
|
Harbeck N, Schmitt M, Meisner C, et al:
Ten-year analysis of the prospective multicentre Chemo-N0 trial
validates American Society of Clinical Oncology (ASCO)-recommended
biomarkers uPA and PAI-1 for therapy decision making in
node-negative breast cancer patients. Eur J Cancer. 49:1825–1835.
2013.
|
|
11.
|
Heuser J: Changes in lysosome shape and
distribution correlated with changes in cytoplasmic pH. J Cell
Biol. 108:855–864. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Montcourrier P, Silver IA, Farnoud R, Bird
I and Rochefort H: Breast cancer cells have a high capacity to
acidify extracellular milieu by a dual mechanism. Clin Exp
Metastasis. 15:382–392. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Chalbos D, Vignon F, Keydar I and
Rochefort H: Estrogens stimulate cell proliferation and induce
secretory proteins in a human breast cancer cell line (T47D). J
Clin Endocrin Metab. 55:276–283. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Martínez-Zaguilán R, Seftor EA, Seftor RE,
Chu YW, Gillies RJ and Hendrix MJ: Acidic pH enhances the invasive
behavior of human melanoma cells. Clin Exp Metastasis. 14:176–186.
1996.PubMed/NCBI
|
|
15.
|
Heussen C and Dowdle EB: Electrophoretic
analysis of plasminogen activators in polyacrylamide gels
containing sodium dodecyl sulfate and copolymerized substrates.
Anal Biochem. 102:196–202. 1980. View Article : Google Scholar
|
|
16.
|
Vassalli JD and Belin D: Amiloride
selectively inhibits the urokinase-type plasminogen activator. FEBS
Lett. 214:187–191. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Maynadier M, Ramirez JM, Cathiard AM, et
al: Unliganded estrogen receptor alpha inhibits breast cancer cell
growth through interaction with a cyclin-dependent kinase inhibitor
(p21(WAF1)). FASEB J. 22:671–681. 2008. View Article : Google Scholar
|
|
18.
|
Garcia M, Capony F, Derocq D, Simon D, Pau
B and Rochefort H: Characterization of monoclonal antibodies to the
estrogen-regulated Mr 52,000 glycoprotein and their use in MCF7
cells. Cancer Res. 45:709–716. 1985.PubMed/NCBI
|
|
19.
|
Brouillet JP, Spyratos F, Hacene K, Fauque
J, Freiss G, Dupont F, Maudelonde T and Rochefort H:
Immunoradiometric assay of pro-cathepsin D in breast cancer
cytosol: relative prognostic value versus total cathepsin D. Eur J
Cancer. 29A:1248–1251. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Tissot JD, Hauert J and Bachmann F:
Characterization of plasminogen activators from normal human breast
and colon and from breast and colon carcinomas. Int J Cancer.
34:295–302. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Christensen L, Wiborg Simonsen AC,
Heegaard CW, Moestrup SK, Andersen JA and Andreasen PA:
Immunohistochemical localization of urokinase-type plasminogen
activator, type-1 plasminogen-activator inhibitor, urokinase
receptor and α2-macroglobulin receptor in human breast carcinomas.
Int J Cancer. 66:441–452. 1996.
|
|
22.
|
Jankun J and Skrzypczak-Jankun E:
Molecular basis of specific inhibition of urokinase plasminogen
activator by amiloride. Cancer Biochem Biophys. 17:109–123.
1999.PubMed/NCBI
|
|
23.
|
Simon DI, Xu H and Vaughan DE: Cathepsin
D-like aspartyl protease activity mediates the degradation of
tissue-type plasminogen activator/plasminogen activator inhibitor-1
complexes in human monocytes. Biochim Biophys Acta. 1268:143–145.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Rochefort H and Liaudet-Coopman E:
Cathepsin D in cancer metastasis: a protease and a ligand. Acta
Pathol Microb Immunol Scand. 107:86–95. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Rofstad K, Mathiesen B, Kindem K and
Galappathi K: Acidic extracellular pH promotes experimental
metastasis of human melanoma cells in athymic nude mice. Cancer
Res. 66:6699–6707. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Ryan TJ, Seeger JI, Kumar SA and Dickerman
HW: Estradiol preferentially enhances extracellular tissue
plasminogen activators of MCF-7 breast cancer cells. J Biol Chem.
259:14324–14327. 1984.PubMed/NCBI
|
|
27.
|
Jessani N, Humphrey M, McDonald WH, et al:
Carcinoma and stromal enzyme activity profiles associated with
breast tumor growth in vivo. Proc Natl Acad Sci USA.
101:13756–13761. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Briozzo P, Badet J, Capony F, Pieri I,
Montcourrier P, Barritault D and Rochefort H: MCF7 mammary cancer
cells respond to bFGF and internalize it following its release from
extracellular matrix: a permissive role of cathepsin D. Exp Cell
Res. 194:252–259. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Liaudet E, Garcia M and Rochefort H:
Cathepsin D maturation and its stimulatory effect on metastasis are
prevented by addition of KDEL retention signal. Oncogene.
9:1145–1154. 1994.PubMed/NCBI
|
|
30.
|
Richo G and Conner GE: Proteolytic
activation of human procathepsin D. Adv Exp Med Biol. 306:289–296.
1991. View Article : Google Scholar
|
|
31.
|
Rozhin J, Sameni M, Ziegler G and Sloane
BF: Pericellular pH affects distribution and secretion of cathepsin
B in malignant cells. Cancer Res. 54:6517–6525. 1994.PubMed/NCBI
|
|
32.
|
Tate KM, Higgins DL, Holmes WE, Winkler
ME, Heyneker HL and Vehar GA: Functional role of proteolytic
cleavage at arginine-275 of human tissue plasminogen activator as
assessed by site-directed mutagenesis. Biochemistry. 26:338–343.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Berg DT and Grinnell BW: Signal and
propeptide processing of human tissue plasminogen activator:
activity of a pro-tPA derivative. Biochem Biophys Res Commun.
179:1289–1296. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Cajot JF, Kruithof EK, Schleuning WD,
Sordat B and Bachmann F: Plasminogen activators, plasminogen
activator inhibitors and procoagulant analyzed in twenty human
tumor cell lines. Int J Cancer. 38:719–727. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Suzuki Y, Mogami H, Ihara H and Urano T:
Unique secretory dynamics of tissue plasminogen activator and its
modulation by plasminogen activator inhibitor-1 in vascular
endothelial cells. Blood. 113:470–478. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Rijken DC, Hoegee-de Nobel E, Jie AF,
Atsma DE, Schalij MJ and Nieuwenhuizen W: Development of a new test
for the global fibrinolytic capacity in whole blood. J Thromb
Haemost. 6:151–157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Sharma M, Ownbey RT and Sharma MC: Breast
cancer cell surface annexin II induces cell migration and
neoangiogenesis via tPA dependent plasmin generation. Exp Mol
Pathol. 88:278–286. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Krieger M and Herz J: Structures and
functions of multi-ligand lipoprotein receptors: macrophage
scavenger receptors and LDL receptor-related protein (LRP). Annu
Rev Biochem. 63:601–637. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Beaujouin M, Prébois C, Derocq D, et al:
Pro-cathepsin D interacts with the extracellular domain of the beta
chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth. J
Cell Sci. 123:3336–3346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Mason SD and Joyce JA: Proteolytic
networks in cancer. Trends Cell Biol. 4:228–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Pagano M, Capony F and Rochefort H:
Pro-cathepsin D can activate in vitro pro-cathepsin B secreted by
ovarian cancers. C R Acad Sci III. 309:7–12. 1989.(In French).
|
|
42.
|
Nishimura Y, Kawabata T, Furuno K and Kato
K: Evidence that aspartic proteinase is involved in the proteolytic
processing event of procathepsin L in lysosomes. Arch Biochem
Biophys. 271:400–406. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Danø K, Behrendt N, Hoyer-Hansen G,
Johnsen M, Lund LR, Ploug M and Romer J: Plasminogen activation and
cancer. Thromb Haemost. 93:676–681. 2005.
|
|
44.
|
Fredriksson L, Li H, Fieber C, Li X and
Eriksson U: Tissue plasminogen activator is a potent activator of
PDGF-CC. EMBO J. 23:37932004. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Seeds NW, Basham ME and Haffke SP:
Neuronal migration is retarded in mice lacking the tissue
plasminogen activator gene. Proc Natl Acad Sci USA. 96:14118–14123.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Carmeliet P, Schoonjans L, Kieckens L, et
al: Physiological consequences of loss of plasminogen activator
gene function in mice. Nature. 368:419–424. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Duffy MJ, O’Grady P, Devaney D, O’Siorain
L, Fennelly JJ and Lijnen HR: Tissue-type plasminogen activator, a
new prognostic marker in breast cancer. Cancer Res. 48:1348–1349.
1988.PubMed/NCBI
|
|
48.
|
Chappuis PO, Dieterich B, Sciretta V,
Lohse C, Bonnefoi H, Remadi S and Sappino AP: Functional evaluation
of plasmin formation in primary breast cancer. J Clin Oncol.
19:2731–2738. 2001.PubMed/NCBI
|
|
49.
|
Kortlever RM, Higgins PJ and Bernards R:
Plasminogen activator inhibitor-1 is a critical downstream target
of p53 in the induction of replicative senescence. Nature Cell
Biol. 8:877–884. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Conover CA and De Leon DD: Acid-activated
insulin-like growth factor-binding protein-3 proteolysis in normal
and transformed cells. Role of cathepsin D. J Biol Chem.
269:7076–7080. 1994.PubMed/NCBI
|
|
51.
|
Elzi DJ, Lai Y, Song M, Hakala K,
Weintraub ST and Shiio Y: Plasminogen activator inhibitor
1-insulin-like growth factor binding protein 3 cascade regulates
stress-induced senescence. Proc Natl Acad Sci USA. 109:12052–12057.
2012. View Article : Google Scholar : PubMed/NCBI
|
